DBV Technologies S.A. (DBVT) SEC filings

DBVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as DBVTF

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 6/30

$11.43−0.45 (-3.79%)

Close on Nov 12, 2026Market cap $718.69MP/E –Yield –

SEC filings

40 of DBV Technologies's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Oct 28, 2026	SEC EDGAR
Current report	8-K	Oct 28, 2026	Oct 28, 2026	SEC EDGAR
Current report	8-K	Sep 29, 2026	Sep 30, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Jul 16, 2026	SEC EDGAR
Current report	8-K	Jul 16, 2026	Jul 16, 2026	SEC EDGAR
Current report	8-K	Jun 29, 2026	Jun 29, 2026	SEC EDGAR
Current report	8-K	Jun 3, 2026	Jun 5, 2026	SEC EDGAR
Current report	8-K	Jun 3, 2026	Jun 3, 2026	SEC EDGAR
Proxy statement	DEF 14A	Jun 3, 2026	May 11, 2026	SEC EDGAR
Current report	8-K	Apr 30, 2026	May 5, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	Apr 30, 2026	SEC EDGAR
Current report	8-K	Apr 30, 2026	Apr 30, 2026	SEC EDGAR
Annual report, amended	10-K/A	Dec 31, 2025	Apr 30, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 26, 2026	SEC EDGAR
Current report	8-K	Mar 26, 2026	Mar 26, 2026	SEC EDGAR
Current report	8-K	Feb 28, 2026	Mar 2, 2026	SEC EDGAR
Current report	8-K	Jan 16, 2026	Jan 20, 2026	SEC EDGAR
Current report	8-K	Dec 16, 2025	Dec 16, 2025	SEC EDGAR
Current report	8-K	Oct 30, 2025	Oct 30, 2025	SEC EDGAR
Current report	8-K	Oct 28, 2025	Oct 29, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Oct 28, 2025	SEC EDGAR
Current report	8-K	Sep 18, 2025	Sep 18, 2025	SEC EDGAR
Current report	8-K	Sep 5, 2025	Sep 5, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Jul 29, 2025	SEC EDGAR
Current report	8-K	Jul 29, 2025	Jul 29, 2025	SEC EDGAR
Current report	8-K	Jun 25, 2025	Jun 25, 2025	SEC EDGAR
Current report	8-K	Jun 11, 2025	Jun 11, 2025	SEC EDGAR
Proxy statement	DEF 14A	Jun 11, 2025	May 15, 2025	SEC EDGAR
Annual report, amended	10-K/A	Dec 31, 2024	May 14, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	Apr 30, 2025	SEC EDGAR
Current report	8-K	Apr 30, 2025	Apr 30, 2025	SEC EDGAR
Annual report, amended	10-K/A	Dec 31, 2024	Apr 28, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Apr 11, 2025	SEC EDGAR
Current report	8-K	Mar 27, 2025	Mar 31, 2025	SEC EDGAR
Current report	8-K	Mar 24, 2025	Mar 24, 2025	SEC EDGAR
Current report	8-K	Jan 8, 2025	Jan 8, 2025	SEC EDGAR
Current report	8-K	Dec 16, 2024	Dec 18, 2024	SEC EDGAR
Current report	8-K	Dec 13, 2024	Dec 16, 2024	SEC EDGAR
Current report	8-K	Dec 11, 2024	Dec 11, 2024	SEC EDGAR
Current report	8-K	Nov 11, 2024	Nov 12, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in DBV Technologies's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-2 reverse split on Jun 7, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is DBVT.

Compare: DBVT vs ATRA · DBVT vs FATE · DBVT vs TCRX · DBVT vs MOLN · DBVT vs ELOX

Revenue growth-31.6% · median -38.4%

Operating margin-5431.6% · median -2246.8%

Net margin-5405.3% · median -2219.2%

Company	Revenue	Growth
TCRX	$5.19M	-38.4%
FATE	$4.75M	-33.4%
ATRA	$3.97M	-97.4%
DBVT	$3.84M	-31.6%
MOLN	–	–
ELOX	–	–

Company

Next earnings (est.): Mar 25, 2027, during market hours
Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 125
Auditor: Deloitte & Associes
SEC CIK: 1613780

Advertisement
300 × 250

See a number that looks wrong?